S. Nathaniel Gardiner's Insider Trades & SAST Disclosures
S. Nathaniel Gardiner's most recent trade in Enanta Pharmaceuticals Inc was a trade of 5,187 Common Stock done at an average price of $9.0 . Disclosure was reported to the exchange on Feb. 26, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern S. Nathaniel Gardiner.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc | S. Nathaniel Gardiner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.99 per share. | 26 Feb 2024 | 5,187 | 75,688 (0%) | 0% | 9.0 | 46,631 | Common Stock |
| Enanta Pharmaceuticals Inc | S. Gardiner Nathaniel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 5,187 | 77,813 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathaniel Gardiner S. | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 3,320 | 71,474 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | S. Gardiner Nathaniel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 12 Feb 2024 | 973 | 70,501 (0%) | 0% | 12.4 | 12,075 | Common Stock |
| Enanta Pharmaceuticals Inc | S. Nathaniel Gardiner | Sr. VP & General Counsel | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 05 Dec 2023 | 2,412 | 68,154 (0%) | 0% | 9.6 | 23,228 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.49 per share. | 01 Dec 2023 | 1,595 | 70,566 (0%) | 0% | 9.5 | 15,137 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2023 | 83,000 | 83,000 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Apr 2023 | 6,667 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 18 Apr 2023 | 6,667 | 79,980 (0%) | 0% | 30 | 200,010 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 11,747 | 80,048 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 9,250 | 68,301 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 13 Feb 2023 | 6,735 | 73,313 (0%) | 0% | 52.8 | 355,406 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.33 per share. | 01 Dec 2022 | 1,055 | 59,051 (0%) | 0% | 44.3 | 46,768 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 21,000 | 60,106 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 2,419 | 47,196 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 957 | 46,239 (0%) | 0% | 62.5 | 59,803 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 615 | 44,777 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 28,400 | 28,400 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 6,800 | 59,783 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 5,250 | 0 | - | - | Restricted Stock Units | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 5,250 | 43,788 (0%) | 0% | - | Common Stock | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.52 per share. | 15 Dec 2020 | 1,540 | 42,248 (0%) | 0% | 42.5 | 65,481 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 03 Dec 2020 | 1,667 | 38,538 (0%) | 0% | 30 | 50,010 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2020 | 1,667 | 13,667 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 30,800 | 30,800 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 7,600 | 36,871 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2020 | 1,666 | 15,334 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 05 Aug 2020 | 1,666 | 29,271 (0%) | 0% | 30 | 49,980 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges